CYP1A2 Gene: Drug Target and Biomarker for Disease (G1544)

Target Name: CYP1A2

NCBI ID: G1544

CYP1A2

CYP1A2 Gene: Drug Target and Biomarker for Disease

CYP1A2 (microsomal monoxygenase), also known as CYP1A2 gene or CYP1A2 protein, is a gene that encodes for a protein known as cytochrome P450 1A2. This gene is a member of the cytochrome P450 gene family, which is responsible for the production of a wide range of enzymes that are involved in various cellular processes. One of the functions of these enzymes is to metabolize drugs, including many statins, which are used to treat cholesterol and cardiovascular disease.

The CYP1A2 gene is located on chromosome 11.1 and has been implicated in the metabolism of a wide variety of drugs, including many statins, as well as a number of other compounds. Studies have shown that individuals with certain genetic variations in the CYP1A2 gene may have altered levels of these drugs in their bodies, which can lead to potential drug interactions or toxicity.

In addition to its role in drug metabolism, CYP1A2 has also been shown to play a key role in the regulation of cellular processes that are involved in the development and maintenance of the nervous system. This includes the production of neurotransmitters, such as dopamine and serotonin, which are involved in the transmission of signals in the brain.

The CYP1A2 gene has also been implicated in a number of diseases and disorders, including cardiovascular disease, depression, and some forms of cancer. For example, studies have shown that individuals with certain genetic variations in the CYP1A2 gene may be at increased risk of developing cardiovascular disease, including heart attack, stroke, and high blood pressure.

Given the wide range of functions and interactions of CYP1A2, it is a promising target for drug development and research. Many companies are currently working on developing drugs that target this gene, with the goal of using these drugs to treat a wide range of conditions, including cardiovascular disease, depression, and some forms of cancer.

In addition to its potential as a drug target, CYP1A2 has also been shown to be a potential biomarker for a number of diseases. This is because the expression of this gene has been shown to be involved in the development and progression of a wide range of diseases, including cardiovascular disease, depression, and some forms of cancer.

For example, studies have shown that individuals with certain genetic variations in the CYP1A2 gene may be at increased risk of developing cardiovascular disease, including heart attack, stroke, and high blood pressure. This is because these variations have been shown to alter the levels of a number of compounds that are involved in the regulation of blood pressure, including Angiotensin II, a hormone that causes blood vessels to constrict and raise blood pressure.

In addition, CYP1A2 has also been shown to be involved in the production of neurotransmitters, such as dopamine and serotonin, which are involved in the transmission of signals in the brain. This suggests that changes in the levels of this gene may be involved in the development and progression of some forms of neurodegenerative disease.

Overall, the CYP1A2 gene is a promising target for drug development and research, with the potential to treat a wide range of conditions, including cardiovascular disease, depression, and some forms of cancer. While further research is needed to fully understand the functions and interactions of this gene, its potential as a biomarker and drug target is an exciting area of study that is being actively explored by researchers around the world.

Protein Name: Cytochrome P450 Family 1 Subfamily A Member 2

Functions: A cytochrome P450 monooxygenase involved in the metabolism of various endogenous substrates, including fatty acids, steroid hormones and vitamins (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Mechanistically, uses molecular oxygen inserting one oxygen atom into a substrate, and reducing the second into a water molecule, with two electrons provided by NADPH via cytochrome P450 reductase (NADPH--hemoprotein reductase) (PubMed:9435160, PubMed:10681376, PubMed:11555828, PubMed:12865317, PubMed:19965576). Catalyzes the hydroxylation of carbon-hydrogen bonds (PubMed:11555828, PubMed:12865317). Exhibits high catalytic activity for the formation of hydroxyestrogens from estrone (E1) and 17beta-estradiol (E2), namely 2-hydroxy E1 and E2 (PubMed:11555828, PubMed:12865317). Metabolizes cholesterol toward 25-hydroxycholesterol, a physiological regulator of cellular cholesterol homeostasis (PubMed:21576599). May act as a major enzyme for all-trans retinoic acid biosynthesis in the liver. Catalyzes two successive oxidative transformation of all-trans retinol to all-trans retinal and then to the active form all-trans retinoic acid (PubMed:10681376). Primarily catalyzes stereoselective epoxidation of the last double bond of polyunsaturated fatty acids (PUFA), displaying a strong preference for the (R,S) stereoisomer (PubMed:19965576). Catalyzes bisallylic hydroxylation and omega-1 hydroxylation of PUFA (PubMed:9435160). May also participate in eicosanoids metabolism by converting hydroperoxide species into oxo metabolites (lipoxygenase-like reaction, NADPH-independent) (PubMed:21068195). Plays a role in the oxidative metabolism of xenobiotics. Catalyzes the N-hydroxylation of heterocyclic amines and the O-deethylation of phenacetin (PubMed:14725854). Metabolizes caffeine via N3-demethylation (Probable)

The "CYP1A2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CYP1A2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets